HLA-A*03:01 KRAS G12V peptide Tetramer peptide (Recombinant) (STJP001777)
SPECIFICATIONS
HostHEK293 cells NA
ConjugationUnconjugated
ImmunogenDNA sequence encoding the Human (HLA-A*03:01) AA25-305 [accession# P04439] and the B2M protein AA2-119 [accession# P61769], fused to the mutant G12V KRAS epitope VVVGAVGVGK.This complex includes a C terminal polyHis AVI tag and was expressed in HEK c
General Information
| Short Description | Recombinant-HLA-A*03:01 KRAS G12V peptide Tetramer is synthetically produced from the Human HLA-A*03:01 AA25-305/B2M protein AA2-119 sequence and is suitable for use in western blot applications. |
| Host | HEK293 cells NA |
| Note | STRICTLY FOR FURTHER RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Product Properties
| Conjugation | Unconjugated |
| Dilution Range | A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers. NA |
| Formulation | Lyophilised from 0.2 ยตm filtered PBS solution pH7.4 NA |
| Storage Instruction | The lyophilized protein is stable for at least 2 years from date of receipt at-20ยฐC C. NA |
| Endotoxin | Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/ยตg (1EU/ยตg). NA |
Target Information
| Accession Number | P61769 |
| Immunogen | DNA sequence encoding the Human (HLA-A*03:01) AA25-305 [accession# P04439] and the B2M protein AA2-119 [accession# P61769], fused to the mutant G12V KRAS epitope VVVGAVGVGK.This complex includes a C terminal polyHis AVI tag and was expressed in HEK c |
| Immunogen Region | Human HLA-A*03:01 AA25-305/B2M protein AA2-119 NA |